Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Nerve-Pain drug quiet chronic pelvic pain?

NCT ID NCT07818577

Symptom relief Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 17, 2026 · Updated 3 times

Summary

Researchers are testing whether adding pregabalin to standard conservative care reduces chronic pelvic pain in women. About 308 women aged 18 to 65 with moderate to severe pain lasting more than six months take part. Half receive standard care alone, which includes education and body awareness therapy, and half receive standard care plus oral pregabalin for 12 weeks. The main measure is pain intensity change on a 0-to-10 scale, with side effects tracked throughout.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pregabalin, an oral nerve-pain drug
What this could lead to
If it helps, pregabalin could become a standard add-on for women whose chronic pelvic pain does not improve with conservative care alone.
What could go wrong
Chronic pelvic pain often has many causes, so a single drug may not work for everyone. Pregabalin can cause dizziness, drowsiness, and weight gain, and the open-label design means expectations could color how participants report pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 308 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18-65 years. * Diagnosis of chronic pelvic pain based on the 2022 revisions to the European Association of Urology criteria. * Use of, or willingness to use, effective contraception to avoid pregnancy during the study period. * Moderate to severe chronic pelvic pain lasting more than 6 months. Moderate pain is defined as a VAS score of 4-6, and severe pain as a VAS score of 7 or higher. * Sufficient cognitive and language skills to comply with all study requirements. Exclusion Criteria: * Dysmenorrhea as the sole pain complaint. * History of malignancy. * Current or previous use of pregabalin. * Planned surgery within the next 6 months. * Contraindication to pregabalin or a previous adverse reaction to pregabalin. * Current use of gonadotropin-releasing hormone agonists with inability or unwillingness to discontinue treatment. * Pregnancy, breastfeeding, or intention to become pregnant within the next 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pelvic pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic pelvic pain Chronic pelvic pain syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.